IgG4-Related Hypertrophic Pachymeningitis
JAMA Neurol 71:785-793, Lu, L.X.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014
Addition of Hyperacute MRI Aids in Patient Selection, Decreasing the Use of Endovascular Stroke Therapy
Stroke 45:467-472, Wisco, D.,et al, 2014
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Subacute Sclerosing Panencephalitis
Adams & Victors Principles of Neurology, Chp 33, pg 766, Ropper, A.H.,et al, 2014
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Herpes Simplex Virus Encephalitis:Clinical Manifestations,Diagnosis and Outcome in 106 Adult Patients
J Clin Virol 60:112-118, Sili,U.,et al, 2014
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Subacute Sclerosing Panencephalitis
www.MedLink.com, February, Auwaeter,P.G.&Johnson,R.T., 2013
Interdependence and Contributions of Sun Exposure and Vitamin D to MRI Measures in Multiple Sclerosis
JNNP 84:1075-1081, 1066, Zivadinov, R.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013
Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013
Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013
Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Clinicopathologic Conference, Blind and Confused, Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 70:932-936, Sharma, V.,et al, 2013
Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013
Brain Abnormalities as an Initial Manifestation of Neuromyelitis Optica Spectrum Disorder
MSJ 17:1107-1112, Kim, W.,et al, 2013
Clinical Spectrum of CNS Aquaporin-4 Autoimmunity
Neurol 78:1179-1185, Kim, S.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013
Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013
Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balos Concentric Lesions
Intern Med 52:1517-1521, Masuda, H.,et al, 2013
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Emerging Subspecialties in Neurology: Neuroimmunology
Neurol 79:e178-e180, Clardy, S., 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Should we be nervous about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurologic opinion
JNNP 83:1216-1221, Currie, S.,et al, 2012
Distinct Lesion Morphology at 7-T MRI Differentiates Neuromyelitis Optica from Multiple Sclerosis
Neurol 79:708-714, Sinnecker, T.,et al, 2012